ArticleJournal of Taibah University Medical Sciences2026
A promising therapeutic biomaterial: CHX@ZnO-HA/PSSS nanocomposites enable pH-Dependent infection eradication and bone regeneration in osteomyelitis.
Article in Journal of Taibah University Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on CHX@ZnO-HA/PSSS nanocomposites for osteomyelitis.Journal of Taibah University Medical Sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Osteomyelitis is a considerable clinical problem, necessitating multifunctional biomaterials that can concurrently manage infection and facilitate bone tissue regeneration. In this study, a chlorhexidine-loaded zinc oxide-hydroxyapatite/poly(sodium 4-styrene sulfonate) (CHX@ZnO-HA/PSSS) nanocomposite for possible therapeutic scaffold applications was manufactured and characterized. Methods: The nanocomposite was synthesized using a chemical precipitation process and studied using Fourier transform-infrared spectroscopy, X-ray diffraction, scanning electron microscopy-energy dispersive X-ray spectroscopy, and transmission electron microscopy to assess its chemical composition, crystallinity, and morphology. The Results: Characterization tests demonstrated the effective incorporation of the amorphous PSSS/CHX layer onto the crystalline ZnO-HA framework. Studies using SBF indicated the time-dependent bioactivity, characterized by the development of a dense, bone-like apatite layer by day 7. Drug release analysis indicated a biphasic, sustained pattern, achieving 40% cumulative release of CHX over 24 h at pH 7.4, regulated by Fickian transport kinetics. Biological assays demonstrated that the CHX@ZnO-HA/PSSS composite markedly improved cell survival (97%), accelerated wound closure in scratch tests, and upregulated essential osteogenic genes relative to the untreated progenitor control group. Conclusion: The CHX@ZnO-HA/PSSS composite exhibited good cytocompatibility, low apoptotic induction, and high
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.